GlassScriptPhysician profile
Trey K Forward
NPI 1912575531
$1,784.49
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $284 · 2023: $712 · 2024: $788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,500.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $475.62 | 2023-2024 | |
| Organon LLC | $268.51 | 2022-2023 | Nexplanon |
| Viiv Healthcare Company | $245.02 | 2023-2024 | Apretude, Dovato, Cabenuva |
| Lilly USA, LLC | $93.63 | 2023-2024 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $86.75 | 2023-2024 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $74.41 | 2023-2024 | Otezla, Repatha |
| Teva Pharmaceuticals USA, INC. | $62.78 | 2023-2024 | Austedo Xr, Ajovy |
| Merck Sharp & Dohme LLC | $55.01 | 2023-2024 | Delstrigo, Pifeltro, Dificid |
| Gilead Sciences, INC. | $51.21 | 2023-2024 | |
| Lundbeck LLC | $46.30 | 2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $44.13 | 2023 | Rexulti, Abilify Maintena |
| Novo Nordisk INC | $42.15 | 2023-2024 | Rybelsus, Ozempic |
| Boston Scientific Corporation | $40.58 | 2023-2024 | Watchman Flx, Advantage System |
| Indivior INC. | $32.74 | 2023-2024 | Sublocade |
| Neurocrine Biosciences, INC. | $31.76 | 2023-2024 | Ingrezza, Ongentys |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $27.29 | 2023 | Gemtesa |
| Mylan Specialty L.P. | $27.15 | 2022-2023 | Yupelri |
| Hologic Sales and Service, LLC | $18.75 | 2023 | Aptima, Thinprep 2000 Processor |
| Ascensia Diabetes Care US INC. | $16.65 | 2023 | |
| Nestle Healthcare Nutrition INC. | $16.03 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.32 | 2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.70 | 2023 | Xifaxan, Trulance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trey Forward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.